You haven't got a death sentence. You've got a chronic disease.
In 2014, Carol Irving was handed a fifteen-month prognosis and sent home to grieve a future she was told she would not have. Nearly twelve years on, she walks her neighborhood daily — not in defiance of medicine, but because of it. Her survival through Pertuzumab targeted therapy reflects a quiet revolution in oncology, one that has doubled survival rates for HER2-positive breast cancer in a single decade. Her story is less a miracle than a testament to what becomes possible when science is given the time and funding to find its answers.
- A stage 4 diagnosis with liver metastases in 2014 gave Carol Irving fifteen months to live — a sentence delivered in clinical language that left her weeping herself to sleep.
- Pertuzumab, a targeted therapy that binds directly to HER2-positive tumor proteins and cuts off their growth signals, offered a path that conventional prognosis had not accounted for.
- Within six months, both liver tumors had vanished entirely — a complete response that prompted her oncologist to reframe her future from terminal countdown to manageable chronic disease.
- HER2-positive breast cancer survival rates have doubled in ten years, validating the clinical trial investments that made treatments like Carol's possible.
- Now walking 100 kilometres in June for the Big Bold Walk initiative, Carol redirects her survival into advocacy — urging others to see research funding not as charity, but as the mechanism that keeps people alive.
When Carol Irving felt a lump in late 2014, the diagnosis that followed was unsparing: stage four breast cancer, spread to her liver, with fifteen months to live. She went home and wept the kind of grief that exhausts you into sleep. It felt, she would later say, like a door slamming shut on everything still ahead of her.
What changed her trajectory was a drug called Pertuzumab — a targeted therapy engineered to seek out the specific protein overproduced by HER2-positive breast cancers, one of the disease's most aggressive forms. It binds to the tumor directly, cutting off the signals that allow it to grow. Within six months of beginning treatment, Carol's two liver tumors had disappeared entirely. Her physician offered a reframing that would reshape her entire sense of the future: not a death sentence, but a chronic disease. The shift, she said, was seismic.
Her experience is no longer exceptional. A 2025 landmark study confirmed that survival rates for HER2-positive breast cancer had doubled over the preceding decade — a direct consequence of targeted therapy advances and the clinical trials that produced them. Carol understood this not as a statistic but as the precise reason she was still alive to see her grandchildren grow.
That understanding is what drew her to the Big Bold Walk, an initiative asking participants to cover 100 kilometres in June to raise funds for breast cancer research. By mid-month she had walked more than half the distance and raised $1,200. She was careful, though, to resist the competitive spirit she noticed in some fellow walkers — the point, she insisted, was awareness and funding, not mileage. Since launching in 2023, the initiative has raised $2.1 million for clinical trials.
For Carol, the walk carries a dimension beyond fundraising. Cancer treatment is a solitary experience, she explained — friends and family can offer comfort, but only fellow survivors truly understand what it means to be handed a countdown. Today, her treatment amounts to one appointment every three months, with no side effects. She walks, plays golf, visits the local pub. She is living the life she was told she would not have, and walking to make sure others get the same chance.
In late 2014, Carol Irving felt a lump in her breast and did what anyone would do—she called her doctor. The diagnosis arrived like a door slamming shut: stage four cancer, already spread to her liver. The oncologist's words were blunt. Fifteen months. That was the timeline they gave her.
She went home and wept. Not every night, she would later say, but deeply—the kind of crying that exhausts you into sleep. A death sentence, delivered in a clinical voice, in a room that smelled like antiseptic and bad news.
Nearly twelve years later, Carol was walking daily through her neighborhood, raising money for the very research that had saved her life. She felt better than she had in decades. The transformation came through a drug called Pertuzumab, a targeted therapy designed to hunt down a specific protein produced by HER2-positive breast cancers—one of the disease's most aggressive variants. The drug binds to that protein and attaches directly to the tumor, starving it of the signals it needs to grow.
Within six months of starting treatment, Carol experienced what doctors call a complete response. The two tumors on her liver simply vanished. One of her physicians reframed her entire future in a single sentence: "You haven't got a death sentence. You've got a chronic disease." The shift was seismic. From terminal to manageable. From countdown to life.
Her case is not unique anymore, though it would have been a decade ago. A landmark study published in 2025 showed that survival rates for HER2-positive breast cancer patients had doubled over the past ten years—a direct result of advances in targeted therapy and the clinical trials that made those advances possible. Carol understood this viscerally. Without continued investment in research, she would not be alive. Without the scientists and doctors who had pursued these treatments, she would have been gone before her grandchildren were old enough to remember her.
So when she heard about the Big Bold Walk—an initiative asking people to walk 100 kilometers in June to raise funds for breast cancer research—she signed up. By mid-month, she had already covered more than half the distance and raised $1,200. But Carol was careful about how she framed her participation. She noticed other walkers turning it into a competition, comparing their daily mileage, trying to outdo one another. That wasn't the point, she said. The point was getting the word out, making people understand that research saves lives—that it had saved hers.
Since its launch in 2023, the Big Bold Walk has raised $2.1 million for clinical trials. The initiative welcomes everyone: survivors, family members, friends. For Carol, the walk was also a way to connect with others who understood what she had endured. Cancer treatment is a solitary experience, she explained. Friends and family can cook your meals and listen to your fears, but they cannot fix it for you. They cannot know what it feels like to be told you have fifteen months left. A community of survivors, though—they understand in a way that requires no explanation.
These days, her treatment regimen barely intrudes on her life. One appointment every three months. No side effects. She walks, she plays golf, she visits the local pub. She is living the life she was told she would not have. And she is walking to make sure others get the same chance.
Notable Quotes
I didn't cry every night, I just sobbed myself to sleep. It's just a horrible thing.— Carol Irving, on learning her diagnosis
Cancer research saved my life.— Carol Irving
The Hearth Conversation Another angle on the story
When you heard that fifteen-month prognosis, did you believe it?
I think part of me did and part of me refused to. You hear those words and they land like a stone, but you're still breathing, still here. It's hard to accept that your body has already decided when you'll be gone.
And then Pertuzumab changed that equation entirely.
It did. But what strikes me now is that it only worked because someone, somewhere, decided to fund the research. This drug didn't exist ten years before I got sick. If I'd been diagnosed then, I'd be gone.
That's why you're walking.
Exactly. It's not abstract for me. I know what the alternative looks like. I lived in that alternative for six months before the tumors disappeared.
You mentioned it's a lonely experience. Does walking with others change that?
Completely. You realize you're not the only one who's been terrified, who's lost someone, who's had to rebuild their life from scratch. That shared understanding—it's not something you can get from a doctor or a therapist. You need to hear it from someone who's actually lived it.
What do you want people to understand about cancer research that they might not already know?
That it's not some distant, abstract thing. It's the difference between being here and not being here. It's the difference between my grandchildren knowing me and them not. Every dollar matters because every dollar is someone's life.